All Articles by Author:

Danielle Corrigan

Nanoparticle-Induced Chemoresistance: The Emerging Modulatory Effects of Engineered Nanomaterials on Human Intestinal Cancer Cell Redox Metabolic Adaptation

[Nanoscale] Investigators screened several representative food-borne comparator engineered nanomaterials and reported that human colon cancer cells could insidiously exploit ZnO nanoparticle-induced adaptive response to acquire resistance against several chemotherapeutic drugs.

NudCD1 as a Prognostic Marker in Colorectal Cancer and Its Role in the Upregulation of Cellular Spindle Assembly Checkpoint Genes and LIS1 Pathways

[BMC Cancer] Scientists investigated the role of NudCD1 in spindle assembly checkpoint regulation and in the prognosis of colorectal cancer.

Repurposing Metformin as a Potential Treatment for Inflammatory Bowel Disease: Evidence from Cell to the Clinic

[International Immunopharmacology] Scientists discuss the beneficial effects of metformin on IBD using the results of in vitro, in vivo, and clinical studies.

Transcriptional Switch of Hepatocytes Initiates Macrophage Recruitment and T-Cell Suppression in Endotoxemia

[Journal of Hepatology] The spatial and temporal changes in hepatocytes and non-parenchymal cell types were validated by multiplex immunofluorescence staining, bulk transcriptomic sequencing, or flow cytometry.

TIPE1 Promotes Liver Regeneration by Enhancing Ros-FoxO1 Axis Mediated Autophagy

[FEBS Journal] Hepatic Tipe1 deficiency decreased the level of reactive oxygen species in hepatocytes, which led to the inhibition of FoxO1 acetylation and LC3I to LC3II conversion, and p62 accumulation.

Knockdown of Hepatocyte Perilipin-3 Mitigates Hepatic Steatosis and Steatohepatitis Caused by Hepatocyte CGI-58 Deletion in Mice

[Journal of Molecular Biology] Scientists test whether the deletion of a major lipid droplet protein alleviates fatty liver pathogenesis caused by alpha/beta hydrolase domain containing 5 deficiency in hepatocytes.

Popular

Challenges and Opportunities in Combining Radiotherapy and Immunotherapy for Localized Pancreatic Cancer

[Nature Reviews Gastroenterology & Hepatology] Expanding preclinical and clinical literature from PDAC and other oncological indications identifies novel approaches through which radiation therapy–immunotherapy combinations could improve local and systemic disease control in patients with PDAC.

Developmental and MAPK-Responsive Transcription Factors Regulate Distinct Malignant Cell States and Associated Genetic Dependencies in Pancreatic Cancer

[Nature Genetics] Single-cell master regulator analysis of multiple pancreatic ductal adenocarcinoma cohorts identified malignant cells in three co-existing, molecularly distinct developmental lineage states, with distinct histopathological morphologies and spatial architecture.

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

[US FDA] The US FDA approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule.